Department of Endocrinology and Metabolism C, Aarhus University Hospital, Aarhus, Denmark.
Clin Endocrinol (Oxf). 2009 Dec;71(6):798-807. doi: 10.1111/j.1365-2265.2009.03557.x. Epub 2009 Feb 25.
Bone metabolism is only superficially described in familiar hypocalciuric hypercalcaemia (FHH). We describe and compare biochemical and osteodensitometric variables in FHH and primary hyperparathyroidism (PHPT) and assess whether they can improve the diagnostic discrimination between the groups.
Cross-sectional.
Sixty-six FHH patients with known calcium-sensing receptor (CASR) gene mutations and 147 PHPT patients.
We determined calcium, creatinine, phosphate, magnesium, parathyroid hormone (PTH), 25OHD, 1,25(OH)(2) D and alkaline phosphatase (AP) in plasma, NTx/creatinine ratio in urine and calculated the calcium/creatinine clearance ratio (CCCR). We performed dual energy X-ray absorptiometry at the lumbar spine, hip, forearm and whole body.
When compared with normal controls, the FHH patients had increased levels of PTH and AP with normal U-NTx and regional Z-scores. Increased phenotypic expression of CASR mutations in terms of hypercalcaemia was associated with higher lumbar spine bone mineral density, but not with bone markers. FHH were younger and leaner than the PHPT patients. They had comparable plasma Ca(2+) and 25OHD, but lower levels of PTH, 1,25(OH)(2) D, AP and U-NTx. They had higher Z-scores in the hip and in the forearm. We achieved the best discrimination between groups by multiplying CCCR with AP, 1,25(OH)(2) D and PTH, but the difference between the area under the curves by receiver operating characteristic analysis remained insignificant.
Familiar hypocalciuric hypercalcaemia is associated with increased PTH and AP compared to normal controls, but not with bone loss irrespective of the severity of the CASR mutations. A multiplicative model including CCCR, AP, 1,25(OH)(2) D and PTH insignificantly improved the power of the CCCR to differentiate between FHH and PHPT. However, we still recommend CASR gene analysis in patients with a CCCR <0.020.
熟知的低钙尿钙过多症(FHH)仅对骨代谢进行了初步描述。我们描述并比较了 FHH 和原发性甲状旁腺功能亢进症(PHPT)的生化和骨密度计量学变量,并评估它们是否可以改善两组之间的诊断区分度。
横断面研究。
66 名已知钙敏感受体(CASR)基因突变的 FHH 患者和 147 名 PHPT 患者。
我们测定了血浆中的钙、肌酐、磷酸盐、镁、甲状旁腺激素(PTH)、25OHD、1,25(OH)(2)D 和碱性磷酸酶(AP),尿液中的 NTx/肌酐比值,并计算了钙/肌酐清除率比值(CCCR)。我们在腰椎、臀部、前臂和全身进行了双能 X 射线吸收法骨密度测定。
与正常对照组相比,FHH 患者的 PTH 和 AP 水平升高,而 U-NTx 和局部 Z 评分正常。CASR 基因突变的表型表达在高钙血症方面的增加与腰椎骨密度增加有关,但与骨标志物无关。FHH 患者比 PHPT 患者年轻且更瘦。他们的血浆 Ca(2+)和 25OHD 水平相当,但 PTH、1,25(OH)(2)D、AP 和 U-NTx 水平较低。他们的臀部和前臂 Z 评分较高。我们通过将 CCCR 与 AP、1,25(OH)(2)D 和 PTH 相乘,获得了最佳的组间区分度,但通过接收者操作特征分析,曲线下面积的差异仍然没有统计学意义。
与正常对照组相比,熟知的低钙尿钙过多症与 PTH 和 AP 升高有关,但与骨丢失无关,无论 CASR 基因突变的严重程度如何。包括 CCCR、AP、1,25(OH)(2)D 和 PTH 的乘法模型显著提高了 CCCR 区分 FHH 和 PHPT 的能力。然而,我们仍建议对 CCCR<0.020 的患者进行 CASR 基因分析。